| AZD1480 |
Influence on angiogenesis |
Immunostaining |
50.00 mg/kg |
Renca (xenograft0 |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
0.10 µM |
EC |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
0.50 µM |
EC |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
1.00 µM |
EC |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
0.10 µM |
HUVEC |
Homo sapiens |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
0.50 µM |
HUVEC |
Homo sapiens |
BALB/c |
|
|
| AZD1480 |
Influence on cell motility |
Tube formation assay |
1.00 µM |
HUVEC |
Homo sapiens |
BALB/c |
|
|
| AZD1480 |
Influence on tumor metastasis |
Number of nodules |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on protein activity in metastatic tumor |
Western Blot |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
p-STAT3 |
|
| AZD1480 |
Influence on protein activity in metastatic tumor |
Western Blot |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
STAT3 |
|
| AZD1480 |
Influence on protein activity in metastatic tumor |
Western Blot |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on protein activity in metastatic tumor |
Western Blot |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Influence on protein activity in metastatic tumor |
Western Blot |
50.00 mg/kg |
Renca |
Mus musclus |
BALB/c |
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
0.50 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
0.50 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
0.50 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
1.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
1.00 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
1.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
2.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
2.00 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
2.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
3.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
3.00 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition |
MTS Assay |
3.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
0.50 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
0.50 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
0.80 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
0.80 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
1.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
1.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
1.50 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
1.50 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
2.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
2.00 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
2.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Apoptosis Analysis |
Flow cytometry |
3.00 µM |
RPMI 8226 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell Viability |
DIMSCAN analysis |
1.00 µM |
PBMC |
Mus musculus |
|
|
|
| AZD1480 |
Cell Viability |
DIMSCAN analysis |
2.00 µM |
PBMC |
Mus musculus |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
0.50 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
0.50 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
1.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
1.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
2.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
2.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
3.00 µM |
Kms.11 |
Homo sapiens |
|
|
|
| AZD1480 |
Cell viability inhibition in presence of IL6 |
MTS Assay |
3.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Influence on protein activity in presence of IL6 |
Immunoprecipitation |
0.50 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Influence on protein activity in presence of IL6 |
Immunoprecipitation |
1.00 µM |
U266 |
Homo sapiens |
|
|
|
| AZD1480 |
Influence on protein activity in presence of IL6 |
Immunoprecipitation |
0.50 µM |
U266 |
Homo sapiens |
|
|
|
